Synopsis
Synopsis
0
CEP/COS
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Cp 690,550
2. Cp 690550
3. Cp-690,550
4. Cp-690550
5. Cp690550
6. Tasocitinib
7. Tofacitinib
8. Xeljanz
1. 540737-29-9
2. Tasocitinib Citrate
3. Xeljanz
4. Cp-690550 Citrate
5. Tofacitinib (citrate)
6. Tofacitinib (cp-690550) Citrate
7. Xeljanz Xr
8. Tofacitinib Citrate [usan]
9. Cp-690,550-10
10. Tasocitinib Monocitrate
11. 540737-29-9 (citrate)
12. Cp-690550-10
13. Cp 690550 Citrate
14. O1ff4div0d
15. 3-((3r,4r)-4-methyl-3-(methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile 2-hydroxypropane-1,2,3-tricarboxylate
16. Chebi:71197
17. 1-piperidinepropanenitrile, 4-methyl-3-(methyl-7h-pyrrolo(2,3-d)pyrimidin-4-ylamino)- Beta-oxo-, (3r,4r)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
18. 2-hydroxypropane-1,2,3-tricarboxylic Acid; 3-[(3r,4r)-4-methyl-3-[methyl({7h-pyrrolo[2,3-d]pyrimidin-4-yl})amino]piperidin-1-yl]-3-oxopropanenitrile
19. 2-hydroxypropane-1,2,3-tricarboxylic Acid;3-[(3r,4r)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile
20. Unii-o1ff4div0d
21. Mfcd11616529
22. 3-{(3r,4r)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile 2-hydroxypropane-1,2,3-tricarboxylate
23. 3-{(3r,4r)-4-methyl-3-[methyl-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile Citrate Salt
24. 3-{(3r,4r)-4-methyl-3-[methyl-(7h-pyrrolo[2,3-d]pyrimidin-4-yl}-amino]-piperidin-1-yl)-3-oxo-propionitrile Citrate Salt
25. Xeljanz (tn)
26. Tofacitinib Monocitrate
27. Tasocitinib Citric Acid Salt
28. Cep-18770(delanzomib)
29. Mls006010058
30. Schembl1374185
31. Chembl2103743
32. Tofacitinib Citrate (jan/usan)
33. Amy4175
34. Dtxsid80202404
35. Ex-a204
36. Tofacitinib Citrate [jan]
37. C16h20n6o.c6h8o7
38. Tofacitinib Monocitrate [mi]
39. Hy-40354a
40. S5001
41. Tofacitinib Citrate [who-dd]
42. Akos022178222
43. Cp-690550 - Tofacitinib Citrate
44. Tofacitinib Citrate, >=98% (hplc)
45. Ccg-269730
46. Cs-0928
47. Tofacitinib Citrate [orange Book]
48. Ac-25004
49. As-19392
50. Bt163661
51. Smr004701220
52. Cp-690550 Citrate (tofacitinib Citrate)
53. Tofacitinib Citrate (cp-690550 Citrate)
54. Cp 690550-10
55. D09783
56. Q27139435
57. (3r,4r)-4-methyl-3-(methyl-7h-pyrro Lo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepro Panenitrile Citrate
58. (3r,4r)-4-methyl-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)-?-oxo-1-piperidinepropanenitrile Citrate
59. (3r,4r)-4-methyl-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidine Propanenitrile 2-hydroxy-1,2,3-propanetricarboxylate
60. (3r,4r)-4-methyl-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)-ss-oxo-1-piperidinepropanenitrile Citrate Salt
61. 1-piperidinepropanenitrile, 4-methyl-3-(methyl-7h-pyrrolo(2,3-d)pyrimidin-4-ylamino)-.beta.-oxo-, (3r,4r)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
62. 1-piperidinepropanenitrile,4-methyl-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-,(3r,4r)-,2-hydroxy-1,2,3-propanetricarboxylate(1:1)
63. 3-((3r,4r)-4-methyl-3-(methyl(7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxo-propanenitrile2-hydroxypropane-1,2,3-tricarboxylate (1:1)
64. 3-((3r,4r)-4-methyl-3-(methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile Mono Citrate Salt
65. 3-{(3r,4r)-4-methyl-3-[methyl-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile Mono Citrate Salt
Molecular Weight | 504.5 g/mol |
---|---|
Molecular Formula | C22H28N6O8 |
Hydrogen Bond Donor Count | 5 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 8 |
Exact Mass | 504.19686187 g/mol |
Monoisotopic Mass | 504.19686187 g/mol |
Topological Polar Surface Area | 221 Ų |
Heavy Atom Count | 36 |
Formal Charge | 0 |
Complexity | 716 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Xeljanz |
PubMed Health | Tofacitinib (By mouth) |
Drug Classes | Antirheumatic, Musculoskeletal Agent |
Drug Label | XELJANZ is the citrate salt of tofacitinib, a JAK inhibitor.Tofacitinib citrate is a white to off-white powder with the following chemical name: (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo [2,3-d]pyrimidin-4-ylamino)--oxo-1-piperidinepropanenitrile, 2-hy... |
Active Ingredient | Tofacitinib citrate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 5mg base |
Market Status | Prescription |
Company | Pf Prism Cv |
2 of 2 | |
---|---|
Drug Name | Xeljanz |
PubMed Health | Tofacitinib (By mouth) |
Drug Classes | Antirheumatic, Musculoskeletal Agent |
Drug Label | XELJANZ is the citrate salt of tofacitinib, a JAK inhibitor.Tofacitinib citrate is a white to off-white powder with the following chemical name: (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo [2,3-d]pyrimidin-4-ylamino)--oxo-1-piperidinepropanenitrile, 2-hy... |
Active Ingredient | Tofacitinib citrate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 5mg base |
Market Status | Prescription |
Company | Pf Prism Cv |
Janus Kinase Inhibitors
Agents that inhibit JANUS KINASES. (See all compounds classified as Janus Kinase Inhibitors.)
NDC Package Code : 11712-895
Start Marketing Date : 2021-02-19
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
NDC Package Code : 42765-036
Start Marketing Date : 2021-05-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (10kg/10kg)
Marketing Category : BULK INGREDIENT
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
NDC Package Code : 42765-061
Start Marketing Date : 2023-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (4kg/4kg)
Marketing Category : BULK INGREDIENT
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
NDC Package Code : 71796-050
Start Marketing Date : 2022-07-29
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.
NDC Package Code : 52076-6267
Start Marketing Date : 2020-12-08
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 73377-084
Start Marketing Date : 2020-11-03
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 42571-289
Start Marketing Date : 2023-06-12
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (10kg/10kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 68724-1000
Start Marketing Date : 2019-01-12
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 60715-1000
Start Marketing Date : 2012-11-06
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 84206-0094
Start Marketing Date : 2024-08-22
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Tofacitinib Citrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tofacitinib Citrate, including repackagers and relabelers. The FDA regulates Tofacitinib Citrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tofacitinib Citrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Tofacitinib Citrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Tofacitinib Citrate supplier is an individual or a company that provides Tofacitinib Citrate active pharmaceutical ingredient (API) or Tofacitinib Citrate finished formulations upon request. The Tofacitinib Citrate suppliers may include Tofacitinib Citrate API manufacturers, exporters, distributors and traders.
click here to find a list of Tofacitinib Citrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Tofacitinib Citrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Tofacitinib Citrate active pharmaceutical ingredient (API) in detail. Different forms of Tofacitinib Citrate DMFs exist exist since differing nations have different regulations, such as Tofacitinib Citrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Tofacitinib Citrate DMF submitted to regulatory agencies in the US is known as a USDMF. Tofacitinib Citrate USDMF includes data on Tofacitinib Citrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Tofacitinib Citrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Tofacitinib Citrate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Tofacitinib Citrate Drug Master File in Japan (Tofacitinib Citrate JDMF) empowers Tofacitinib Citrate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Tofacitinib Citrate JDMF during the approval evaluation for pharmaceutical products. At the time of Tofacitinib Citrate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Tofacitinib Citrate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Tofacitinib Citrate Drug Master File in Korea (Tofacitinib Citrate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Tofacitinib Citrate. The MFDS reviews the Tofacitinib Citrate KDMF as part of the drug registration process and uses the information provided in the Tofacitinib Citrate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Tofacitinib Citrate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Tofacitinib Citrate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Tofacitinib Citrate suppliers with KDMF on PharmaCompass.
A Tofacitinib Citrate written confirmation (Tofacitinib Citrate WC) is an official document issued by a regulatory agency to a Tofacitinib Citrate manufacturer, verifying that the manufacturing facility of a Tofacitinib Citrate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Tofacitinib Citrate APIs or Tofacitinib Citrate finished pharmaceutical products to another nation, regulatory agencies frequently require a Tofacitinib Citrate WC (written confirmation) as part of the regulatory process.
click here to find a list of Tofacitinib Citrate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Tofacitinib Citrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Tofacitinib Citrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Tofacitinib Citrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Tofacitinib Citrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Tofacitinib Citrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Tofacitinib Citrate suppliers with NDC on PharmaCompass.
Tofacitinib Citrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tofacitinib Citrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tofacitinib Citrate GMP manufacturer or Tofacitinib Citrate GMP API supplier for your needs.
A Tofacitinib Citrate CoA (Certificate of Analysis) is a formal document that attests to Tofacitinib Citrate's compliance with Tofacitinib Citrate specifications and serves as a tool for batch-level quality control.
Tofacitinib Citrate CoA mostly includes findings from lab analyses of a specific batch. For each Tofacitinib Citrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tofacitinib Citrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Tofacitinib Citrate EP), Tofacitinib Citrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tofacitinib Citrate USP).
LOOKING FOR A SUPPLIER?